Company Overview of Altor BioScience Corporation
Altor BioScience Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of immunotherapeutic agents for the treatment of cancer, viral infections, and inflammatory and autoimmune diseases. Its product candidates include ALT-801, a T-cell receptor-targeted immunotherapeutic for cancer; ALT-836, a monoclonal antibody-based tissue factor antagonist treatment of patients with acute respiratory distress syndrome and acute lung injury; and ALT-803, an IL-15 superagonist for patients with solid and hematological tumors/metastatic melanoma. The company’s product candidates also include ALT-802, a p53-TCR (T-cell receptors)/IgG1 fusion protein for treat...
2810 North Commerce Parkway
Miramar, FL 33025-3958
Founded in 2002
Key Executives for Altor BioScience Corporation
Chief Financial Officer and Vice President of Business Development
Vice President of Research & Development
Consulting Medical Director and Member of Clinical Advisory Board
Director of Regulatory Compliance
Compensation as of Fiscal Year 2014.
Altor BioScience Corporation Key Developments
Altor BioScience Corporation Presents at BioFlorida Annual Conference, Oct-14-2014 11:15 AM
Oct 11 14
Altor BioScience Corporation Presents at BioFlorida Annual Conference, Oct-14-2014 11:15 AM. Venue: Harbor Beach Marriott, Ft. Lauderdale, Florida, United States. Speakers: Warren Marcus, Scientist and Business Development Associate.
Altor BioScience Corporation and Shenzhen Beike Biotechnology Co., Ltd Announce License Agreement for Immunotherapeutic ALT-803 in China
Sep 10 14
Altor BioScience Corporation and Shenzhen Beike Biotechnology Co. Ltd. (Beike), announced that they have entered into a license agreement to develop and commercialize ALT-803, Altor's proprietary Interleukin-15 (IL-15) based superagonist complex, in China. Under the terms of the agreement, Altor has granted Beike an exclusive license for the research, development, manufacture and commercialization of ALT-803 for therapeutic uses in all human disease indications in China. As part of the agreement, Altor will receive an up-front fee of USD 4 million and could potentially receive over USD 200 million in development and sales milestones, and tiered double-digit royalties based on sales of licensed products. Beike has also made a strategic equity investment of approximately USD 5 million into Altor. Beike will have marketing rights for licensed products in China, and Altor will retain marketing rights in all other countries.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 10, 2014
Most Searched Private Companies
Sponsored Financial Commentaries